All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IO102,IO103,Nivolumab
Therapeutic Area: Oncology Product Name: IO102
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: HBM Healthcare Investment
Deal Size: $153.9 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 13, 2021
Details:
IO Biotech intends to use the net proceeds of the transaction towards the funding of clinical trials for its early and late-stage immuno-oncology programs, including a large randomized trial for IO102 and IO103 with anti-PD-1 monoclonal antibodies in metastatic melanoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IO102,IO103,Nivolumab
Therapeutic Area: Oncology Product Name: IO102
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
The FDA decision to grant breakthrough therapy was based on data from the MM1636 Phase 1/2 clinical trial with 30 patients with metastatic melanoma receiving IO102, IO103 and anti-PD-1.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Enapotamab Vedotin
Therapeutic Area: Oncology Product Name: HuMax-AXL-ADC
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
Genmab will not advance the development of enapotamab vedotin as the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IO102,IO103,Nivolumab
Therapeutic Area: Oncology Product Name: IO102
Highest Development Status: Phase I/ Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
According to the abstract, the combination of IO102 and IO103 vaccines and nivolumab was shown to be safe with encouraging early efficacy data; an overall response rate (ORR) of 79 percent was reached and 45 percent of patients achieved a complete response.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Endovion,Fluorouracil,Leucovorin Calcium
Therapeutic Area: Oncology Product Name: SCO-101
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2020
Details:
First part of the trial aimed at establishing the safety, tolerability and Maximum Tolerated Dose of SCO-101 in combination with FOLFIRI. One patient has obtained stable disease, according to RECIST version 1.1 at 8 weeks after starting the treatment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Epcoritamab
Therapeutic Area: Oncology Product Name: DuoBody-CD3xCD20
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $3,900.0 million Upfront Cash: $750.0 million
Deal Type: Collaboration June 10, 2020
Details:
The companies will partner to develop Genmab's next-generation bispecific antibody programs, epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Epcoritamab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
A list of accepted Industry-sponsored abstracts featured at the congress includes two abstracts on epcoritamab (DuoBody®-CD3xCD20), one on HexaBody®-CD38, one on DuoHexaBody®-CD37 and four daratumumab abstracts.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Epcoritamab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2020
Details:
The presentation will demonstrate continued solid progress in Genmab's development of epcoritamab (DuoBody-CD3xCD20).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SCO-101
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2020
Details:
Phase II trial of SCO-101 treats a critical condition with no satisfactory treatment choice, thus Scandion has agreed to continue the research of colorectal cancer with patients resistant to FOLFIRI.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IO102,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IO102
Highest Development Status: Phase I/ Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2020
Details:
The Safety Monitoring Committee has recommended to continue the trial without modifications as the futility boundary was successfully passed.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
